Fusarium oxysporum f.sp. chrysonthemi is a pathogen recently reported in Italy on four economically important ornamental crops belonging to the Compositae family: chrysanthemum (Chrysanthemum morifolium), Paris daisy (Argyranthemum frutescens), African daisy (Osteospermum sp.) and gerbera (Gerbera jamesonii). The risk of transmission of the pathogen among these species is high because the hosts are frequently cultivated in the same nursery. The susceptibility of 24 Paris daisy and 12 chrysanthemum cultivars to 10 isolates of F. oxysporum f. sp. chrysanthemi and 3 isolates of F. oxysporum of different origin and to one isolate of F. tracheiphilum from gerbera was tested. Among the tested chrysanthemum cultivars, "Menthise bianco", "Cottonball", "Super Yellow" and "Meribel" were resistant to all the tested strains, while Pingpong gel was resistant to 10 out of 12 isolates. Among the 24 tested cultivars of Paris daisy, only "Sole mio", "Butterfly" and "Maria" were resistant to all isolates of F. oxysporum f.sp. chrysanthemi and to F. tracheiphilum. The results obtained in this work suggest the need of devoting more attention to resistance to Fusarium wilt while developing new varieties of both chrysanthemum and Paris daisy, since only few varieties are resistant to all strains tested.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evidence-based guideline: premature ovarian insufficiency.
Hum Reprod Open
December 2024
Monash Centre for Health Research and Implementation (MCHRI), Monash University, Clayton, Australia.
Study Question: How should premature/primary ovarian insufficiency (POI) be diagnosed and managed based on the best available evidence from published literature?
Summary Answer: The current guideline provides 145 recommendations on symptoms, diagnosis, causation, sequelae, and treatment of POI.
What Is Known Already: Premature ovarian insufficiency (POI) presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include adverse effects on quality of life; fertility; and bone, cardiovascular, and cognitive health.
Evidence-based guideline: Premature Ovarian Insufficiency.
Fertil Steril
December 2024
Monash Centre for Health Research and Implementation (MCHRI), Monash University, Clayton, Australia.
Study Question: How should premature/primary ovarian insufficiency (POI) be diagnosed and managed, based on the best available evidence from published literature?
Summary Answer: The current guideline provides 145 recommendations on symptoms, diagnosis, causation, sequelae and treatment of POI.
What Is Known Already: Premature ovarian insufficiency (POI) presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include adverse effects on quality of life; fertility; and bone, cardiovascular and cognitive health.
Evidence-based guideline: premature ovarian insufficiency.
Climacteric
December 2024
Monash Centre for Health Research and Implementation (MCHRI), Monash University, Clayton, VIC, Australia.
Study Question: How should premature/primary ovarian insufficiency (POI) be diagnosed and managed, based on the best available evidence from published literature?
Summary Answer: The current guideline provides 145 recommendations on symptoms, diagnosis, causation, sequelae and treatment of POI.
What Is Known Already: POI presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include adverse effects on quality of life, on fertility and on bone, cardiovascular and cognitive health.
A new freshwater prawn, Macrobrachium ngankeeae n. sp., is described from two rivers in the Kaimana Regency on the southern coast of Papua Barat Province, Indonesia.
View Article and Find Full Text PDFA randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
Clin Exp Rheumatol
August 2024
Department of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.
Objectives: The type I interferon pathway is a promising target for treatment of patients with systemic sclerosis (SSc). Here, we describe the design of a multinational, randomised phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis (DAISY).
Methods: DAISY includes a 52-week double-blind, placebo-controlled treatment period, a 52-week open-label active treatment period, and a 12-week safety follow-up period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!